Angiodynamics (ANGO) Cash & Equivalents (2010 - 2026)

Angiodynamics (ANGO) has 17 years of Cash & Equivalents data on file, last reported at $37.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 15.53% year-over-year to $37.8 million; the trailing twelve-month figure through Feb 2026 stood at $37.8 million (down 15.53% YoY), and the FY2025 full-year result was $55.9 million, down 26.51% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $37.8 million, down from $41.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $78.5 million in Q1 2024 and bottomed at $23.9 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $44.6 million (2023), against an average of $46.0 million.
• The widest annual swing landed in 2022, when Cash & Equivalents sank 56.14%; it then soared 160.54% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $29.9 million in 2022, then jumped by 103.96% to $60.9 million in 2023, then retreated by 11.18% to $54.1 million in 2024, then slipped by 23.02% to $41.6 million in 2025, then declined by 9.19% to $37.8 million in 2026.
• The last three Cash & Equivalents figures came in at $37.8 million (Q1 2026), $41.6 million (Q4 2025), and $38.8 million (Q3 2025), per Business Quant data.

Peer Comparison